StemCells Inc. moves forward with IND from the FDA

StemCells Inc. announced today that the U.S. Food and Drug Administration, or FDA, has authorized the firm’s Investigational New Drug, or IND, application for clinical testing of its proprietary HuCNS-SC(R) human neural stem cells as a treatment for spinal cord injury.

The company noted that as a first action under this IND, it is working to open U.S. sites for its Phase I/II clinical trial for chronic spinal cord injury, which is currently underway in Switzerland and Canada.

“This IND is a significant step forward for our spinal cord injury program. With regulatory authorization from Switzerland, Canada and now the United States, we have the first international trial of a stem cell therapy for spinal cord injury,” said Stephen Huhn, Vice President, CNS Clinical Research at StemCells Inc.

This is truly a fantastic move forward for chronic spinal cord injury. These ongoing human trials can be pivotal in getting a treatment or therapy to those already suffering paralysis.

Read more:

This entry was posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, Stem Cell Research and tagged . Bookmark the permalink.